ClinicalTrials.gg
RecruitingNCT06833463TARGETUpdated Apr 2, 2026

Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients

An observational study in Kidney Transplant, sponsored by Chiesi Poland Sp. z o.o.. Recruiting at 6 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Chiesi Poland Sp. z o.o. (part of Chiesi Farmaceutici S.p.A.) · Observational

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

Many people who receive a kidney transplant develop problems with how their body processes sugar (glucose). This includes conditions like prediabetes and diabetes, which can lead to more health issues, such as heart problems and infections.

One of the main medications used after a kidney transplant, called tacrolimus, can contribute to these sugar problems. Tacrolimus helps protect the new kidney, but it can also harm the cells in the pancreas that produce insulin, a hormone that controls blood sugar. Other factors, such as stress on the body and insulin resistance, can make things worse.

The effect of tacrolimus on blood sugar may depend on how the body processes the drug. Some people break down tacrolimus quickly (fast metabolizers), so they need higher doses to reach the right level in their blood. Others break it down more slowly (slow metabolizers) and require lower doses. Doctors can measure how fast someone metabolizes tacrolimus using aparameter called the concentration-to-dose (C/D) ratio.

This study aims to find out what increases the risk of developing blood sugar problems after a kidney transplant. It will focus on how quickly patients process tacrolimus and whether this affects their risk of developing diabetes. The study will also look at how common these issues are in kidney transplant patients in Poland.

02

Conditions studied

  • Kidney Transplant
03

In context

Lead sponsor

Chiesi Poland Sp. z o.o. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult kidney graft receipients transplanted in the participating study sites

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Recipients of a kidney transplant from a living or deceased donor
  • Standard regimen post-kidney transplantation (KTx) including Envarsus®
  • LCP Tacrolimus therapy initiated from the day of KTx or conversion from another tacrolimus formulation to LCP Tacrolimus by day 8 at the latest, according to the institution's routine practice
  • Informed patient consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of diabetes (type 1 or type 2) treated with diet or glucose-lowering drugs
  • Random glycemia/ levels justifying a diagnosis of diabetes at the time of study enrollment
  • Kidney retransplantation
  • Recipients of a multi-organ transplant
  • Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss
  • Use of flozins for renal or cardiac indications
  • Chronic use of drugs affecting carbohydrate metabolism, such as glucocorticosteroids
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Interventions

  • Treatment with LCP Tacro will begin on the day of the kidney transplant. If a patient is switching from another form of tacrolimus to LCP Tacro, the transition will be completed no later than day 8, following the standard procedures of the medical institution.

06

What researchers measure

Primary outcomes

  1. Glucose metabolism disorders during tacrolimus treatment

    Percentage of patients diagnosed with: * Impaired fasting glucose and/or glucose intolerance (prediabetes) * Post-transplant diabetes mellitus (PTDM) requiring pharmacotherapy,

    Time frame: The endpoint will be determined at 3, 6, and 12 months after transplantation

  2. Risk factors for glucose metabolism disorders

    Odds ratio for glucose metabolism disorders (prediabetes, PTDM) for the following variables: the rate of tacrolimus metabolism, cumulative tacrolimus exposure, cumulative glicocorticosteroid exposure, age, sex, body mass index

    Time frame: 3, 6, and 12 months after transplantation

Secondary outcomes

  1. Fasting glucose

    Changes in mean fasting glucose levels

    Time frame: over a period of 1-12 months

07

Study locations

4 of 6 sites recruiting
  • Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk
    Gdansk, 80-952, Poland
    Recruiting
    • Alicja Dębska-Ślizień, Professor · Contactadeb@gumed.edu.pl · +48 58 584 4700
  • Clinical Department of Nephrology, Dialysis, Transplantology and Internal Medicine
    Krakow, 30-688, Poland
    Recruiting
  • Department of Internal Diseases and Transplant Nephrology, Medical University of Lodz
    Lodz, 90-153, Poland
    Not yet recruiting
    • Ilona Kurnatowska, Professor · Contactkuril@wp.pl · +48 42 291 95 97
  • Department of Transplantology and General Surgery, Provincial Hospital
    Poznan, 60-479, Poland
    Recruiting
    • Maciej Głyda, Professor · Contactglydam@wp.pl · +48 61 821 22 27
  • Department and Clinic of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw
    Warsaw, 02-097, Poland
    Not yet recruiting
  • Department and Clinic of Nephrology and Transplantation Medicine, University Clinical Hospital
    Wroclaw, 50-556, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Oct 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 18, 2025
StartActual
May 29, 2025
Primary completionEst.
Oct 30, 2027
CompletionEst.
Jan 30, 2028
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06833463
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
May 29, 2025
Primary completion
Oct 30, 2027 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Apr 2, 2026

Study contacts

Roman Hożejowski, MD
Contact
r.hozejowski@chiesi.com
+48 22 620 14 21
Tomasz Dębowski, MD, PhD
Contact
t.debowski@chiesi.com
Alicja Dębska-Ślizień, Professor
principal investigator · Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk, Gdansk, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion